Food and Administration Medicine has approved the new instruction for SINGULAIR (montelukast sodium) to prevent the generated exercise bronchoconstriction (EIB; also heard as induced asthma of the exercise) on patient old 15 years and more old. SINGULAIR - first and only spoken tablet approved for this use.

EIB is USUALLY characterized by shortness of breath, is wheezed and breast tightness happened to on exercise. “EIB INFLUENCES upon broad spectrum of the population of the asthma. EIB LIMITS the ability to participate in exercise or physical activity.” said David S. (Read ‘Safe profile SINGULAIR’…)